Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 1,301–1,400 of 1,871
Pharmacotherapeutic Strategies to Prevent Progression to ESKD and Reduce Cardiovascular Risk
Odutayo, A., & Cherney, D. (2024) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00222024 · Cited by 1
Remission revolution; redefining CKD management from slowdown to reversal
Hajian, S., & Far, A. Z. (2026) · Journal of Nephropharmacology · doi:10.34172/npj.2026.12855
“…people with type 2 diabetes and CKD, semaglutide reduced the risk of major kidney outcomes by about 24% compared with placebo, with benefits observed across CKD severity strata and accompanied by clinically meaningful improvements in glycemic control, weight, and blood pressure at two years (34).”
Doumani, G., Theofilis, P., Vordoni, A., Smirloglou, D., & Kalaitzidis, R. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09747-2
Casper, J., Doricic, J., Tian, Z., Willerding, J. M., Glammeier, M., Melk, A., Schmidt-Ott, K. M., & Schmidt, B. M. W. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag198
GLP-1RA pharmacokinetics and clinical effects: focus on cardiac, vascular, and glomerular structures
Barnaba, I., Massari, F., Ciccone, M. M., Caldarola, P., Campanella, C., Ricci, G., & Scicchitano, P. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2714849
“Unlike the renal benefits observed in LEADER and REWIND, which were mainly driven by the reduction in new-onset macroalbuminuria, the FLOW trial provided evidence on harder kidney outcomes, including kidney failure and substantial eGFR decline [70].”
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.030
ERα/SIRT1 signaling mediates the metabolic regulatory benefits of pterostilbene
Huang, T., Chen, X., Chen, D., Yin, J., Yu, B., Yan, H., Zheng, P., & Huang, Z. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113471
Anti-obesity Pharmacotherapy for Transplant Recipients
Haugen, C. E., & Orandi, B. J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01388-1 · Cited by 1
“In a random - ized, placebo-controlled trial among 3,533 patients with CKD and type 2 diabetes, semaglutide 1.0 mg was associ - ated with 24% lower risk of kidney failure, 50% reduction in eGFR, or death from kidney-related or cardiovascular causes [103].”
InfluentialGLP-1 receptor agonist use for obesity in service personnel
Jecks, N., Hughes, C., Macleod, N., & Gifford, R. M. (2025) · BMJ Military Health · doi:10.1136/military-2025-003159
Iwamoto, T., Hidaka, S., Iwamoto, M., & Shibata, H. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109308
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Koca, N., Uyar, S., Şahintürk, Y., Yıldız, H., Prato, S. D., & DeFronzo, R. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03346-2
“Semaglutide has also been shown to exert potent renoprotective effects in the FLOW study [15] and beneficial effects on metabolic dysfunction-associated steatotic liver disease and steato-hepatitis [16] (Fig.”
li, W., Zheng, J., Lv, W., xu, L., Si, K., Liu, Y., Hu, S., Wu, S., Dai, Y., Dong, Q., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10749649/v1
Diabetic kidney disease: exploring mechanistic depths and the future of pharmacological intervention
Rakshe, P. S., & Gaikwad, A. B. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04534-9 · Cited by 3
Chen, Y., Jiang, Z.-H., Chen, J., & Wu, V. (2026) · GeroScience · doi:10.1007/s11357-026-02300-0
Bergia, R. E., Brown, A. W., Braun, M. M., & Messina, M. J. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100689 · Cited by 1
“…myriad health benefits independent of weight loss, opening the possibility of indications for EOMs extending across diverse domains such as cardiovascular [42], renal [43], hepatic [44], neurodegenerative [45], and even behavioral reward domains unrelated to food (e.g., compulsive shopping) [46].”
Buysschaert, M., Abodo, J., Belkhadir, J., & Buysschaert, B. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.04.004
Liu, D., Lin, X., Xie, J., Chen, L., & Wang, N. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113329
Shimada, H., Fukasawa, T., Mizuno, K., Okazawa, Y., Yokogawa, K., & Kawakami, K. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101760
Mallek, W., Wróblewska-Schmude, A., Lesner, A., Piwkowska, A., & Wysocka, M. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118396
La néphropathie diabétique : qu’est-elle devenue en 2025 ?
Marre, M. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.09.003
Tsalouchos, A., & Dattolo, P. C. G. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176550
“The FLOW trial moved the class firmly into kidney outcome therapy: semaglutide reduced major kidney disease events by 24% (HR 0.76, 95% CI 0.66–0.88), cardiovascular death by 29%, and all-cause death by 20% in participants with type 2 diabetes and CKD [45].”
InfluentialCardiorenal Syndrome: Pathophysiology, Management, and the Challenge of Therapeutic Inertia
Gembillo, G., Calabrese, V., Soraci, L., Cicero, L. L., Scapellato, M., Messina, R., Ricca, M. F., Stancanelli, M. R., Corsonello, A., & Santoro, D. (2026) · Medicina · doi:10.3390/medicina62101855
Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL StudyPreprint
Sinha, B., & Ghosal, S. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4879254
Darbà, J., Ascanio, M., & Rodríguez, A. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01611-6
“…trials have demonstrated the effectiveness of sodium-glucose cotrans-porter 2 inhibitors (SGLT2i), finerenone, and semaglutide, and other emerging agents in slowing kidney disease progression, reducing cardiovascular events, and improving outcomes related to CKD-related comorbidities [9–14].”
Rescalli, M. B., Fagiolini, A. M., Carmellini, P., Pinzi, M., Castaldo, F., & Cuomo, A. (2026) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70066 · Cited by 1
Wang, Y., Liu, Z., Wang, S., Lv, C., El-Seedi, H. R., Khalifa, S. A. M., & Wang, H. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70351
“…a phase of cardiovascular- kidney-metabolic integration and therapeutic diversification, characterized by semaglutide, the dual GIP/GLP-1 receptor agonist tirzepatide, obesity and weight loss, chronic kidney disease, fixed-ratio combinations, oral formulations and real-world evidence [25, 28–33].”
Liu, W. J., Zhang, J., Guo, X., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113568
Kazé, A. D., Ndumele, C. E., Jaar, B. G., Santhanam, P., Yeneneh, B. T., Mookadam, F., Tung, R. H., Fonarow, G. C., Crews, D. C., & Echouffo-Tcheugui, J. B. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101903 · Cited by 1
BALDASSARRE, M. P. A., Dalmazi, G. D., Carrieri, F., Centorame, G., Piacentino, L., Coluzzi, S., & Formoso, G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71371
Organ crosstalk in kidney diseases: Insights from metabolic, hormonal and nervous regulation
Lin, S., Zhu, S., & Fu, Y. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124637
Worsening heart failure events in adults with mild-to-moderate chronic kidney disease
Ye, L., Girouard, M. P., Go, A. S., Liu, J. Y., Parikh, R., Tan, T. C., Lee, E. S., Sun, G. E. C., Halaseh, R., Bhatt, A. S., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.107290
STOUGAARD, E. B., & Rossing, P. R. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag131
Self-citationCarretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española · doi:10.1016/j.rce.2025.502352
(2024) · Nursing · doi:10.1097/nsg.0000000000000073
Brandenburg, V. (2026) · Nephrologie aktuell · doi:10.1055/a-2748-5190
Luca, F. D., Troise, D. E., Camporeale, V., Leccese, G., Galloso, F., Cuttano, R., Infante, B., Stallone, G., Ranieri, E., & Netti, G. S. (2026) · Antioxidants · doi:10.3390/antiox15091116 · Cited by 3
“Semaglutide has demonstrated kidney outcome benefit in type 2 diabetes with CKD [201], while MASH data support activity across the broader metabolic disease axis [202].”
Gil, F. M. A., Osoro, I. A., Franch‐Nadal, J., & de la Puente, J. B. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.1.art3
Gabriela Ana, P. U. H. A., & LUNGU, I. (2026) · Medicine and Materials · doi:10.36868/medmater.2026.06.02.07
Zaccardi, F., Aroda, V. R., Arslan, E. G., Bardtrum, L., Goldney, J., Ising, E., Priyadarshini, P., Slater, T., & Davies, M. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70770
“GLP-1 RAs have demonstrated reduced cardio- kidney-metabolic risk in individuals with EOT2D, and semaglutide has shown benefits beyond glycaemia, including weight reduction and fa-vourable cardiovascular and kidney outcomes [22, 24, 49, 50].”
Was ist neu in der Therapie des Typ-2-Diabetes?
Gallwitz, B. (2026) · CME · doi:10.1007/s11298-025-4487-x
Tseng, T., & Chang, R. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.09.010 · Cited by 1
Moyal, J., & Rehany, B. (2026) · University of Toronto Medical Journal · doi:10.33137/utmj.v103i2.46711
Nastase, I., Iordachi, T. F. D., Gurzun, M., Guțu, C., & Sârbu, N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103909 · Cited by 1
“In CKD, these previously described vascular alterations, including increased arterial stiffness and altered hemodynamic load, intensify pulsatile stress within the carotid circulation, thereby accelerating plaque development and progression [30,31,45,46].”
Sjöholm, Å., & Rao, A. D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1808396 · Cited by 1
Ena, J., Carretero‐Gómez, J., Tembra, M. S., Villar, L. L., Pena, C., Rosales‐Castillo, A., Pinilla, N. D., Carrasco-Sánchez, F. J., Merlo, A. B., Soler, A. R., et al. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.102279 · Cited by 1
GLP-1 receptor agonists—a potential therapy for chronic kidney disease?
Boeckhaus, J., Sayer, J. A., & Mabillard, H. R. (2026) · Clinical Science · doi:10.1042/cs20261312
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
Hadjadj, S., Ragot, S., Durocher, L., Bigot‐Corbel, E., Kessler, L., Tauveron, I., Vidal-Trécan, T., Saulnier, P., Gourdy, P., Moret, M., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101772 · Cited by 1
Almahmeed, W. A., Barajas-Gamboa, J. S., Zubaid, M., Al‐Ozairi, E., Shehab, A., Al‐Rasadi, K., Khalil, C. A., Busaidi, N. A., Sindi, F. A., Awan, Z. A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70204
Speer, T. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag039
Chronic Kidney Disease-Associated Cardiomyopathy: Mechanisms and Therapeutic Strategies
Grigoriou, K., Lamprou, V., Chatzichidiroglou, A., Theofilis, P., Iliakis, P., Apostolos, A., Ktenopoulos, N., Karagiannidis, E., Antoniadis, A. P., Fragakis, N., et al. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm51534
Stéatohépatite associée à un dysfonctionnement métabolique (MASH) : prise en charge
Farrugia, M. A., Gual, P., & Anty, R. (2026) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)50657-5
Deng, C.-X., Chen, Z.-M., Tang, Y.-X., Xi, Z.-X., Wang, S.-Y., Wu, H.-Y., Xu, B., & Xu, T.-C. (2026) · World Journal of Pharmacology · doi:10.5497/wjp.v15.i1.113080
Mian, M. H. S., Janahi, K. A. H. A., Tayeb, A., Musaffar, F. M. M., Khalil, N., Toubah, S. H. A., Karim, A. M. A., Almarzooqi, A. M., Sayfoo, F. M., Hamadeh, A., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01888-y
Ayala, R. C. G. (2026) · Revista Salud Integral · doi:10.66778/si.v04n02.08
Branigan, P., Duong, V. N. Y., & Branigan, S. (2026) · Cureus · doi:10.7759/cureus.116039
“Earlier cardiovascular outcome trials reported favorable kidney outcomes, and FLOW provided dedicated randomized kidney outcome evidence for semaglutide in patients with T2DM and CKD [17].”
Adiposopathy-Based Chronic Diseases and Therapeutic Role of Semaglutide
Tiwari, A., Pahuja, V., Vipin, V. P., Erande, S. G., Indurkar, S. A., Kumar, A., Saha, I., Lahiri, K. D., Kishore, R., Alok, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_21_26
Obesity and heart failure—the role of GLP-1 receptor agonists
Simonis, G., & Schatz, U. (2025) · Herz · doi:10.1007/s00059-025-05312-2
Overview of Medications Used to Treat Type 2 Diabetes
White, J. R., & Ramsbacher, N. C. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch05
Mechanisms of Podocyte Injury in Kidney Allografts
Barsotti, G. C., Menon, M. C., Naik, A. S., & Rao, A. (2025) · Kidney360 · doi:10.34067/kid.0000001091
Impact of GAD-65 antibody detection on antihyperglycemic therapy in T2D
Halliburton, S., Herber, E., Pantalone, K. M., Parker, M., & Soric, A. (2026) · Endocrine Connections · doi:10.1530/ec-25-0785
“If a trend of reduced utilization of non-insulin antihyperglycemic agents after GAD-65 AAb detection is demonstrated in future studies, it would be important to (14, 18).”
Teunis, C. J., Collins, T. J. C., Oostveen, R. F., Neele, A. E., de Winther, M. P. J., Nurmohamed, N. S., Heijmans, J., Winkelmeijer, M., Dzobo, K. E., Cooper, M. E., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag627
Pharmacologic management of diabetic kidney disease and other considerations
Mead, D. R., Rios, I. P., Cooks, S., Peters, A., Rodgers, A., & Fruecht, M. (2025) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000306
Klein, K. R., WYSHAM, C. H., Tuttle, K. R., Davies, M. J., Cox, D., Chen, J., Wu, W.-S., Denning, M., Liu, R., Ludwig, L., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01865-9 · Cited by 3
Self-citationAllaham, L., King, B. J., Ali, F., GUPTA, I., Metuku, R., Nieto, I., Lurie, A., Amer, F. N., Reddy, R., & Alzghoul, B. N. (2026) · Lung · doi:10.1007/s00408-026-00939-2
Orozco‐Beltrán, D. (2025) · Diabetes práctica · doi:10.52102/diabet/manejo.erc.art4
Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial
Tuttle, K. R., Bjornstad, P., Smith, C., Pruijm, M. T., McCown, P. J., Hodgin, J. B., Cherney, D. Z. I., Belmar, N., Chacko, M. M., Das, V., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04674-2 · Cited by 2
Self-citationInnovations in chronic kidney disease and aging
Fadem, S. Z. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34069-7.00031-8
Semaglutid zur Nephroprotektion bei Diabetes mellitus Typ 2
Pavlicek, V. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01509-z
Mehta, A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.06.017
Lau, D. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.12.008
Beavers, C. J., & Greene, S. J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10597-4
Les traitements du diabète de type 2 : les preuves
Bordier, L., & Bauduceau, B. (2026) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2026.100822
Prävention und Progressionshemmung der chronischen Nierenerkrankung
Schmit, D., Lämmerzahl, J. R., Neuhaus, S., & Sellier, A. B. (2026) · Die Nephrologie · doi:10.1007/s11560-026-00911-4
Diabetes/Weight Loss Drug Associated With Risk for Type of Optic Neuropathy
FitzGerald, S. F. (2024) · Neurology Today · doi:10.1097/01.nt.0001050484.50871.d5
wu, Z., Yu, T. Y., Yan, L., Zhen, M., Liang, Y., Guo, T., & He, Y. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5124705
Vashisht, R., Dhruva, S. S., Patel, A. R., Dahm, L., Morris, P., Gonzalez, D. M., Follett, R., Sirota, M., Singh, K., Han, C., et al. (2025) · SSRN Electronic Journal · doi:10.1101/2025.08.13.25333579 · Cited by 2
Prävention von chronischer Nierenkrankheit: Bedarf und Möglichkeiten
Rogge, F., & von Samson‐Himmelstjerna, F. A. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00847-1
Kidney Status and Events Preceding Death in Heart Failure: A Real-world Nationwide StudyPreprint
Zahir, D., Garred, C. H., Carlson, N., et al. (2024) · medRxiv · doi:10.1101/2024.10.15.24315570
Moh, M. C., Low, S. K., Pek, S. L. T., Liu, J., Ang, K., Tang, W. E., Lim, Z., Subramaniam, T., Sum, C. F., & Lim, S. C. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.108953
Heerspink, H. J. L., van Raalte, D. H., Tuttle, K., Cherney, D. Z. I., Bjornstad, P., Cao, D., Dimitriadis, G. K., Linetzky, B., Jouravskaya, I., Bunck, M. C. M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70622 · Cited by 2
Self-citationGLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023
Chu, P. Y., Kelly, A., Hennessy, S., Vajravelu, M. E., Huang, J., & Amaral, S. G. (2026) · PEDIATRICS · doi:10.1542/peds.2025-071971 · Cited by 3
Li, X. M., Zhang, H., Wang, S., Shi, J., Zhang, J., Chen, M., ZHAO, M., Yue, T., & Zheng, X. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71399
Glucagon-like Peptide 1 Receptor Agonists and Risk of Pulmonary HypertensionPreprint
Garry, J. D., Kundu, S., Alcorn, C., Eden, S., Smith, E. K., Greevy, R. A., Tindle, H. A., Freiberg, M. S., & Brittain, E. L. (2025) · medRxiv · doi:10.1101/2025.09.18.25336100
Inkretin-(Co-)Agonisten: Wo geht die Reise hin?
Sonnet, M. (2025) · Info Diabetologie · doi:10.1007/s15034-024-5066-z
Fan, A., Chen, X., Yang, K., Ma, X., Gao, H. T., Wang, B., Fan, G., & Li, L. (2026) · Biomolecules · doi:10.3390/biom16091241
“In patients with established HFrEF, however, the small LIVE and FIGHT trials did not show clinical benefit with liraglutide and raised safety concerns, including increased heart rate and a potential excess of arrhythmic events [167].”
Alternative Perspectives on Obesity and Hypertension
Schulhof, A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000802
Kardiovaskuläre Erkrankungen bei chronischer Nierenerkrankung
Gerdes, C., & Busch, M. (2026) · Nephrologie aktuell · doi:10.1055/a-2827-5317
The Role of GLP-1 Receptor Agonists in Diabetic Kidney Disease: Recent Evidence
Kim, J. H. (2025) · Journal of Korean Diabetes · doi:10.4093/jkd.2025.26.1.5
Diagnosis and Therapy of Diabetes Based on Evidence
Shikata, K. (2025) · Health Evaluation and Promotion · doi:10.7143/jhep.52.370
ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome
Bansal, N., Bjornstad, P., Bress, A. P., Chang, T. I., Cheng, X. S., Estrella, M. M., Go, A. S., Mottl, A. K., Navaneethan, S. D., Neuen, B. L., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001231 · Cited by 3
Therapie der Inflammation in der Nephrologie
Sievers, L. K., & Schmitt, R. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2376-0783
“Zuletzt konnte eine analoge Reduktion der sterilen Inflammation auch unter Behandlung mit dem GLP1-Analogon Semaglutid in der FLOW-Studie ge-zeigt werden [12].”
Diabetes Mellitus and the Increased Risk of Acute Kidney Injury Following Acute Coronary Syndrome
Shah, M. U., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Diabetology · doi:10.3390/diabetology6120148
“Similarly, glucagon-like peptide-1 receptor agonists (GLP-1RAs) also have efficacy in terms of reduced renal risk [26].”
Integrating Clinical Decision Support Systems in CKD Management
Cervantes, C. E., Thiessen‐Philbrook, H., Bitzel, J., Patel, D. M., Menez, S. P., Srialluri, N., Sang, Y., Scott, J., Jaar, B. G., Grams, M. E., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106633
Al-Badri, M. R., Dhaver, S., & Hamdy, O. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70054 · Cited by 1
“Semaglutide was shown to slow the progression of renal impairment in patients with chronic kidney disease [9].”
Behandlung des Typ-2-Diabetes: Wenn der Zucker nur noch Nebenschauplatz ist
Martin, S. (2025) · Info Diabetologie · doi:10.1007/s15034-025-5107-2
Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial
Heerspink, H. J. L., Soler, M. J., Beernink, J. M., Jongs, N., Guldris, S. C., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Apperloo, E. M., Waanders, F., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001051 · Cited by 3
Hypertension and Diabetic Kidney Disease
Leoncini, G., Russo, E., Barnini, C., Viazzi, F. C., & Pontremoli, R. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_8
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.